Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Inovio Pharmaceuticals, Inc.    INO

INOVIO PHARMACEUTICALS, INC.

(INO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Inovio to begin mid-to-late stage study of COVID-19 vaccine candidate in September

share with twitter share with LinkedIn share with facebook
08/10/2020 | 07:03pm EDT

Aug 10 (Reuters) - Inovio Pharmaceuticals Inc expects its experimental COVID-19 vaccine to enter mid-to-late stage study in September and secure U.S. emergency use authorization sometime in 2021, the U.S. vaccine developer said on Monday.

The Plymouth Meeting, Pennsylvania-based company had previously said it would begin mid-stage human studies for the vaccine candidate, INO-4800, this summer.

Shares of the company were down 6% in trading after the bell.

Inovio is in active talks with the U.S. Food and Drug Administration and awaits the agency's approval to begin Phase 2/3 study in September, a company executive said during a post-earnings conference call.

The company in June reported encouraging results from an early stage human trial and received $71 million from the U.S. Department of Defense to scale up production of devices used to administer INO-4800.

Effective vaccines are seen as essential to controlling the pandemic that has claimed more than 731,700 lives worldwide, according to a Reuters tally.

Many drugmakers, including Moderna Inc, Pfizer Inc , Johnson & Johnson, Sanofi and AstraZeneca Plc, are also in various stages of developing a vaccine for COVID-19. (Reporting by Manojna Maddipatla and Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.26% 8479 Delayed Quote.11.17%
INOVIO PHARMACEUTICALS, INC. -0.52% 11.46 Delayed Quote.251.52%
MODERNA, INC. -2.42% 69.11 Delayed Quote.261.71%
PFIZER LIMITED -0.13% 4894.6 End-of-day quote.15.87%
PFIZER, INC. -0.87% 36.385 Delayed Quote.-7.68%
SANOFI -0.04% 85.3 Real-time Quote.-4.79%
share with twitter share with LinkedIn share with facebook
All news about INOVIO PHARMACEUTICALS, INC.
09/29Danger Is Approaching for Coronavirus Vaccine Stocks -- Heard on the Street
DJ
09/29INOVIO PHARMACEUTICALS : Thinking about buying stock in Sorrento Therapeutics, N..
PR
09/29NEWS HIGHLIGHTS : Top Company News of the Day
DJ
09/28NEWS HIGHLIGHTS : Top Company News of the Day
DJ
09/28China's Kangtai gets approval for clinical trial of coronavirus vaccine candi..
RE
09/28NEWS HIGHLIGHTS : Top Company News of the Day
DJ
09/28Diageo, Cleveland-Cliffs rise; Aquestive, Inovio fall
AQ
09/28Diageo, Cleveland-Cliffs rise; Aquestive, Inovio fall
AQ
09/28INOVIO PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (..
AQ
09/28NEWS HIGHLIGHTS : Top Company News of the Day
DJ
More news
Financials (USD)
Sales 2020 6,23 M - -
Net income 2020 -230 M - -
Net Debt 2020 - - -
P/E ratio 2020 -7,78x
Yield 2020 -
Capitalization 1 943 M 1 943 M -
Capi. / Sales 2020 312x
Capi. / Sales 2021 13,4x
Nbr of Employees 190
Free-Float 97,7%
Chart INOVIO PHARMACEUTICALS, INC.
Duration : Period :
Inovio Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INOVIO PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 13,71 $
Last Close Price 11,60 $
Spread / Highest target 116%
Spread / Average Target 18,2%
Spread / Lowest Target -31,0%
EPS Revisions
Managers
NameTitle
J. Joseph Kim President, Chief Executive Officer & Director
Simon X. Benito Chairman
Jacqueline E. Shea Chief Operating Officer & Executive Vice President
Peter D. Kies Chief Financial & Accounting Officer
Laurent M. Humeau Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
INOVIO PHARMACEUTICALS, INC.251.52%1 943
LONZA GROUP AG60.99%46 048
SEATTLE GENETICS, INC.71.27%34 049
IQVIA HOLDINGS INC.2.02%30 150
CELLTRION, INC.42.27%29 576
MODERNA, INC.261.71%27 917